登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07169500,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 50 岁;性别:不限
登记记录的入选字段
Congestive heart failure (New York Heart Association [NYHA] class III or IV), NYHA scores are in Appendix 2
排除标准第 7 条
Malignant tumors other than multiple myeloma within 3 years prior to signing the ICF, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and other in situ cancers at other sites one year after radical surgery, provided there is no ongoing treatment and no signs of recurrence during the screening period;
排除标准第 10 条
ECOG score of 0-1, see Appendix 5 for ECOG scoring;
入选标准第 14 条
Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN)
入选标准第 4 条
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
入选标准第 5 条
Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 40 ml/min
入选标准第 6 条
Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) < 1.5 × ULN, international normalized ratio (INR) < 1.5 × ULN
入选标准第 7 条
Hemoglobin (Hb) ≥ 60 g/L
入选标准第 8 条
Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L (no granulocyte colony-stimulating factor [G-CSF] or other growth factors received within 7 days prior to screening laboratory tests)
入选标准第 9 条
Platelets (PLT) ≥ 50 × 10\^9/L (no platelet transfusion received within 7 days prior to screening laboratory tests)
入选标准第 11 条
Peripheral blood hepatitis B virus (HBV) DNA test value is above the detection limit
排除标准第 14 条
Hepatitis C virus (HCV) antibody positive and peripheral HCV-RNA positive
排除标准第 15 条
Human immunodeficiency virus (HIV) antibody positive
排除标准第 16 条
Female participants of childbearing potential must have a negative pregnancy test and not be breastfeeding; female or male participants of childbearing potential must use effective contraceptive methods or devices for 24 months after cell infusion.
入选标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07169500,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Subjects voluntarily participate in the study and sign the informed consent form (ICF) themselves or through their legal guardian; Confirmed diagnosis of multiple myeloma through flow cytometry or immunohistochemistry; Subjects must have adequate organ function and meet all of the following test results: Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 40 ml/min Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) < 1.5 × ULN, international normalized ratio (INR) < 1.5 × ULN Hemoglobin (Hb) ≥ 60 g/L Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L (no granulocyte colony-stimulating factor [G-CSF] or other growth factors received within 7 days prior to screening laboratory tests) Absolute lymphocyte count (ALC) ≥ 0.5 × 10\^9/L Platelets (PLT) ≥ 50 × 10\^9/L (no platelet transfusion received within 7 days prior to screening laboratory tests) Left ventricular ejection fraction (LVEF) ≥ 45% Blood oxygen saturation (SpO2) ≥ 92% ECOG score of 0-1, see Appendix 5 for ECOG scoring; Expected survival ≥ 3 months; Female participants of childbearing potential must have a negative pregnancy test and not be breastfeeding; female or male participants of childbearing potential must use effective contraceptive methods or devices for 24 months after cell infusion.排除标准:Exclusion Criteria:
History of allergy to any component of the cellular product; Severe heart disease, including but not limited to: Myocardial infarction, coronary angioplasty, or stent implantation within 6 months prior to signing the ICF Unstable angina Severe arrhythmia History of severe non-ischemic cardiomyopathy Congestive heart failure (New York Heart Association [NYHA] class III or IV), NYHA scores are in Appendix 2 Stroke or seizure within 6 months prior to signing the ICF; Autoimmune diseases, immunodeficiency, or other conditions requiring immunosuppressive therapy; Malignant tumors other than multiple myeloma within 3 years prior to signing the ICF, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and other in situ cancers at other sites one year after radical surgery, provided there is no ongoing treatment and no signs of recurrence during the screening period; Presence of uncontrolled active infection; Unstable systemic diseases as judged by the investigator, including but not limited to severe liver, kidney, or metabolic diseases requiring medication. Within one week before lymphocyte collection, the storage device falls under any of the following conditions: Peripheral blood hepatitis B virus (HBV) DNA test value is above the detection limit Hepatitis C virus (HCV) antibody positive and peripheral HCV-RNA positive Human immunodeficiency virus (HIV) antibody positive Syphilis antigen or antibody positive CMV-DNA positive Within one week before lymphocyte collection, use of more than 5 mg/day of prednisone (or an equivalent dose of other corticosteroids); Prior use of any CAR-T cell products or other genetically modified T cell therapies; Prior BCMA-targeted therapy; Vaccination with a live vaccine within 4 weeks before signing the ICF; History of alcoholism, drug abuse, or psychiatric disorders; Other conditions that the investigator deems unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07169500, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07169500,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。